PRMT5 and cancer: PRMT inhibitors were initially reported in the early 2000s, and recently specific inhibitors were designed to specifically target PRMT3, PRMT4, PRMT5, and PRMT6 in preclinical cell culture animal models, revealing the therapeutic and pharmacological potential of targeting PRMTs in cancer [197,198].